Major Depressive Disorder (MDD) is common psychiatric condition that causes significant disability and disease burden.  Treatment for this condition may require multiple medication trials.  Up to thirty percent of individuals with MDD do not receive adequate benefit from several antidepressant drug trials and are considered treatment resistant.  The management of treatment resistant depression (TRD) often requires novel approaches.  One such approach is to use N-methyl-D-aspartate (NMDA) receptor antagonists such as ketamine or esketamine.  This session will review the use of ketamine and esketamine for TRD.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.